OncoMatch/Clinical Trials/NCT07774572
Exploration of Circular RNA in B-cell Hematologic Malignancies
Is NCT07774572 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Investigational product (IP) for lymphoma, b-cell refractory.
Treatment: Investigational product (IP) — This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Confirmed diagnosis of relapsed/refractory (R/R) CD19-positive B-cell malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — disease subtype-specific (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable)
Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable)
Lab requirements
Blood counts
ANC <1.0×10⁹/L, Hb <70 g/L, PLT <50×10⁹/L, lymphocytes ≤0.5×10⁹/L, or coagulation abnormalities (INR/APTT ≥1.5×ULN)
Kidney function
CrCl <50 mL/min by Cockcroft-Gault
Liver function
ALT/AST >2×ULN, or >3×ULN with hepatic involvement; bilirubin >2×ULN, unless Gilbert syndrome
Cardiac function
LVEF ≥ 40% by echocardiogram; uncontrolled ischemic heart disease, NYHA Class III-IV heart failure, or baseline QTcF ≥450 ms (male) / ≥470 ms (female) [excluded]
LVEF ≥ 40% by echocardiogram. Inadequate hematologic function (ANC <1.0×10⁹/L, Hb <70 g/L, PLT <50×10⁹/L, lymphocytes ≤0.5×10⁹/L) or coagulation abnormalities (INR/APTT ≥1.5×ULN). Hepatic impairment (ALT/AST >2×ULN, or >3×ULN with hepatic involvement; bilirubin >2×ULN, unless Gilbert syndrome). Renal impairment (CrCl <50 mL/min by Cockcroft-Gault). Uncontrolled ischemic heart disease, NYHA Class III-IV heart failure, or baseline QTcF ≥450 ms (male) / ≥470 ms (female).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07774572 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages